EJC Supplements
Volume 9, Issue 2 , Pages 36-42, October 2011

Case histories: breast cancer

  • Alessandra Gennari

      Affiliations

    • Division of Medical Oncology, Gdlliera Hospital, Genoa, Italy
    • Corresponding Author InformationCorresponding author. Alessandra Gennari, Division of Medical Oncology, Galliera Hospital, Mura delle Cappuccine 15, 16125 Genoa, Italy. Tel.: +39 010 5634502; fax: +39 010 5634507
    • ,
  • Elisabetta Pietri

      Affiliations

    • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
    • ,
  • Dino Amadori

      Affiliations

    • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy

Article Outline

Keywords:  Anthracycline , Breast cancer , Elderly patients , HER2-positive , Liposomal doxorubicin , Trastuzumab , Triple-negative

No abstract is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Morgan D , Sylvester H , Lucas FL , Miesfeldt S . Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting . Fam Cancer . 2009;8:277–287
  2. Dent R , Trudeau M , Pritchard KI , et al.   Triple-negative breast cancer: clinical features and patterns of recurrence . Clin Cancer Res . 2007;13:4429–4434
  3. Dent R , Hanna WM , Trudeau M , Rawlinson E , Sun P , Narod SA . Pattern of metastatic spread in triplenegative breast cancer . Breast Cancer Res Treat . 2009;115:423–428
  4. Cancello G , Maisonneuve P , Rotmensz N , et al.   Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer . Ann Oncol . 2010;21:1974–1981
  5. Liedtke C , Mazouni C , Hess KR , et al.   Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer . J Clin Oncol . 2008;26:1275–1281
  6. Montagna E , Bagnardi V , Rotmensz N , et al.   Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features . Breast Cancer Res Treat . 2010;124:689–699
  7. Silver DP , Richardson AL , Eklund AC , et al.   Efficacy of neoadjuvant cisplatin in triple-negative breast cancer . J Clin Oncol . 2010;28:1145–1153
  8. Ryan PD , Tung NM , Isakoff SJ , et al.   Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy . J Clin Oncol . 2009;27(Suppl 15S): abs 551.
  9. Torrisi R , Balduzzi A , Ghisini R , et al.   Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel . Cancer Chemother Pharmacol . 2008;62:667–672
  10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials . Lancet . 2005;365:1687–1717
  11. Peto R; for the Early Breast Cancer Trialists' Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. 30th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 13-16 December 2007:plenary lecture 1.
  12. Amir E , Clemons M , Freedman OC , et al.   Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies . J Clin Oncol . 2010;28(Suppl 15s): abs 1007.
  13. Morabito A , Piccirillo MC , Monaco K , et al.   First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment . Oncologist . 2007;12:1288–1298
  14. Miles D , Chan A , Dirix LY , et al.   Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer . J Clin Oncol . 2010;28:3239–3247
  15. O'Shaughnessy J , Osborne C , Pippen J , et al.   Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triplenegative breast cancer (TNBC): results of a randomized phase II trial . J Clin Oncol . 2009;27(Suppl 18s): abs 3.
  16. Muss HB . Adjuvant treatment of elderly breast cancer patients . Breast . 2007;16(Suppl 2):S159–S165
  17. Yancik R , Wesley MN , Ries LA , Havlik RJ , Edwards BK , Yates JW . Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older . JAMA . 2001;285:885–892
  18. Dowsett M , Cuzick J , Ingle J , et al.   Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen . J Clin Oncol . 2010;28:509–518
  19. Giordano SH , Duan Z , Kuo YF , Hortobagyi GN , Goodwin JS . Use and outcomes of adjuvant chemotherapy in older women with breast cancer . J Clin Oncol . 2006;24:2750–2756
  20. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Adjuvant chemotherapy in oestrogenreceptor-poor breast cancer: patient-level meta-analysis of randomised trials . Lancet . 2008;371:29–40
  21. Muss HB , Woolf S , Berry D , et al.   Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer . JAMA . 2005;293:1073–1081
  22. Muss HB , Berry DA , Cirrincione CT , et al.   Adjuvant chemotherapy in older women with early-stage breast cancer . N Engl J Med . 2009;360:2055–2065
  23. Jones S , Holmes FA , O'Shaughnessy J , et al.   Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 . J Clin Oncol . 2009;27:1177–1183
  24. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 . Ann Oncol . 2011;22:1736–1747
  25. Biganzoli L , Licitra S , Claudino W , Pestrin M , Leo AD . Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle? . Eur J Cancer . 2007;43:2270–2278
  26. Chia S , Gradishar W , Mauriac L , et al.   Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT . J Clin Oncol . 2008;26:1664–1670
  27. Howell A , Robertson JF , Quaresma Albano J , et al.   Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment . J Clin Oncol . 2002;20:3396–3403
  28. Wildiers H , Kunkler I , Biganzoli L , et al.   Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology . Lancet Oncol . 2007;8:1101–1115
  29. Aapro M , Monfardini S , Jirillo A , Basso U . Management of primary and advanced breast cancer in older unfit patients (medical treatment) . Cancer Treat Rev . 2009;35:503–508
  30. Colleoni M , Rocca A , Sandri MT , et al.   Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels . Ann Oncol . 2002;13:73–80
  31. Blum JL , Jones SE , Buzdar AU , et al.   Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer . J Clin Oncol . 1999;17:485–493
  32. Batist G , Ramakrishnan G , Rao CS , et al.   Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer . J Clin Oncol . 2001;19:1444–1454
  33. Batist G , Harris L , Azarnia N , Lee LW , Daza-Ramirez P . Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis . Anticancer Drugs . 2006;17:587–595
  34. Harris L , Batist G , Belt R , et al.   Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma . Cancer . 2002;94:25–36
  35. Body JJ , Coleman R , Clezardin P , et al.   International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients . Eur J Cancer . 2007;43:852–858
  36. Perez EA . New treatment strategies in the management of breast cancer . EJC Suppl . 2011;9(2):22–29
  37. Dawood S , Broglio K , Buzdar AU , Hortobagyi GN , Giordano SH . Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review . J Clin Oncol . 2010;28:92–98
  38. Weisgerber-Kriegl U , Cirrincione A , McNiven P . Estimation of the epidemiological effect of trastuzumab over 10 years in 5 European countries . J Clin Oncol . 2008;26(Suppl): abs 6589.
  39. Gianni L , Eiermann W , Semiglazov V , et al.   Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort . Lancet . 2010;375:377–384
  40. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 8-12 December 2010:abs S3-2.
  41. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 8-12 December 2010:abs S3-3.
  42. Smith I , Procter M , Gelber RD , et al.   2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial . Lancet . 2007;369:29–36
  43. Slamon D , Eiermann W , Robert N , et al.   Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC?T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC?TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study . Cancer Res . 2009;69(24 Suppl): abs 62.
  44. Perez E , Suman V , Davidson N , et al.   Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial . Cancer Res . 2009;69(24 Suppl): abs 80.
  45. Curigliano G , Viale G , Bagnardi V , et al.   Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer . J Clin Oncol . 2009;27:5693–5699
  46. Gonzalez-Angulo AM , Litton JK , Broglio KR , et al.   High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller . J Clin Oncol . 2009;27:5700–5706
  47. Cortes J , Di Cosimo S , Climent MA , et al.   Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study . Clin Cancer Res . 2009;15:307–314
  48. Amadori D , Milandri C , Comella G , et al.   A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer . Eur J Cancer . 2011 Jun 10; [Epub ahead of print]
  49. Venturini M , Bighin C , Puglisi F , et al.   A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer . Breast . 2010;19:333–338
  50. Anton A , Ruiz A , Plazaola A , et al.   Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study . Ann Oncol . 2010 Jul 5; [Epub ahead of print]
  51. Seidman AD , Berry D , Cirrincione C , et al.   Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 . J Clin Oncol . 2008;26:1642–1649
  52. Gori S , Colozza M , Mosconi AM , et al.   Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer . Br J Cancer . 2004;90:36–40
  53. Robert N , Leyland-Jones B , Asmar L , et al.   Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer . J Clin Oncol . 2006;24:2786–2792

PII: S1359-6349(11)70008-8

doi:10.1016/S1359-6349(11)70008-8

EJC Supplements
Volume 9, Issue 2 , Pages 36-42, October 2011

Article Tools